Asuragen
Oxford Nanopore Technologies, Bio-Techne Partner to Develop Carrier Screening Assay
The project will leverage Asuragen's long-range PCR and Oxford Nanopore's sequencing capabilities to develop a sequencing workflow for carrier screening.
Thermo Fisher Scientific Deal Expands Possibilities for Exosome Dx Business, Bio-Techne CEO Says
Premium
The deal with Thermo Fisher is for the development of Bio-Techne's second test in its Exosome Diagnostics portfolio, a multigene assay for kidney transplant rejection.
Bio-Techne expects the acquisition will provide it with a basis to build out its IVD presence, given Asuragen's diagnostic tests and regulatory expertise.
Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M
Bio-Techne said Asuragen's headquarters in Austin, Texas includes a scalable 50,000-square-foot manufacturing facility and CLIA-certified laboratory.
Asuragen Receives CE Mark for Spinal Muscular Atrophy Assay
The test can help diagnose spinal muscular atrophy and identify carriers without symptoms who may be at risk of passing the disease to their children.